Key Documents

CUDC 101

Name: CUDC 101
Brand: SIGMA
Price: 215 USD

A potent inhibitor of HDACs and receptor tyrosine kinases

Synonym(s):

7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide, Heptanamide, 7-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-hydroxy

Select a Size

Change View

Pack Size	SKU	Availability	Price
5 mg		Usually ships in 2 weeks.	$215.00

About This Item

Empirical Formula (Hill Notation):

C₂₄H₂₆N₄O₄

CAS Number:

1012054-59-9

Molecular Weight:

434.49

MDL number:

MFCD15528940

UNSPSC Code:

12352200

NACRES:

NA.41

Assay:

≥98% (HPLC)

Quality level:

100

$215.00

Usually ships in 2 weeks.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

color

white

solubility

DMSO: soluble

storage temp.

−20°C

SMILES string

N(O)C(=O)CCCCCCOc1cc2c(ncnc2Nc3cc(ccc3)C#C)cc1OC

InChI

1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)

InChI key

PLIVFNIUGLLCEK-UHFFFAOYSA-N

Related Categories

Epigenetics

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	SML2221	C7249	SML2850
Sigma-Aldrich EPS003 CUDC 101	Sigma-Aldrich SML2221 CU-CPT9a	Sigma-Aldrich C7249 CI-1033	Sigma-Aldrich SML2850 Cediranib
assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
Quality Level 100	Quality Level -	Quality Level 100	Quality Level 100
storage temp. −20°C	storage temp. −20°C	storage temp. −20°C	storage temp. 2-8°C
solubility DMSO: soluble	solubility DMSO: 2 mg/mL, clear	solubility DMSO: >10 mg/mL, H₂O: >10 mg/mL	solubility DMSO: 2 mg/mL, clear
color white	color white to beige	color -	color white to beige

General description

A potent multitargeted inhibitor of histone deacetylase (HDAC) and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), with IC50 values of 4.4, 2.4, and 15.7 nM, respectively.

Displays potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.

related product

Product No.

Description

Pricing

EPI004

Histone Deacetylase 3 (HDAC3) Activity Assay Kit, 100 assays in 96 well plates

EPI005

Histone Deacetylase 3 (HDAC3) Inhibitor Screening Kit, 100 assays in 96 well plates

EPI006

Histone Deacetylase 8 (HDAC8) Activity Assay Kit, 100 assays in 96 well plates

EPI007

Histone Deacetylase 8 (HDAC8) Inhibitor Screening Kit, 100 assays in 96 well plates

EPI008

Histone Deacetylase (HDAC) Inhibitor Set I, Set includes 6 inhibitors

Storage Class

10 - Combustible liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

2B261966

B9A201966V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.

Cheng-Jung Lai et al.

Cancer research, 70(9), 3647-3656 (2010-04-15)

Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers. However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.

Xiong Cai et al.

Journal of medicinal chemistry, 53(5), 2000-2009 (2010-02-11)

By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compounds with potent, multiacting HDAC, EGFR, and HER2

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells.

Ni Sima et al.

Translational oncology, 11(4), 1053-1064 (2018-07-10)

Drug resistance to chemotherapy occurs in many ovarian cancer patients resulting in failure of treatment. Exploration of drug resistance mechanisms and identification of new therapeutics that overcome the drug resistance can improve patient prognosis. Following a quantitative combination screen of

Global Trade Item Number

SKU	GTIN
EPS003-25MG	04061833609583
EPS003-5MG	04061833609590

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service